In addition to the potential application to surgery-free treatment of HER2-positive breast cancer patients, unmethylated HSD17B4 may be used to identify patients who will not benefit from trastuzumab treatment but might benefit from lapatinib. Here, HSD17B4 is linked to breast carcinoma.